8-K: Allakos Reports Q1 2024 Financial Results and Provides Business Update

Allakos Inc. announced its first quarter 2024 financial results, highlighting progress in its AK006 clinical trials and reiterating its cash runway guidance.

Summary

• Allakos reported a net loss of $71.1 million for the first quarter of 2024, compared to a net loss of $42.4 million in the same period of 2023.
• The company's cash, cash equivalents, and investments totaled $139.3 million at the end of Q1 2024, a decrease of $31.5 million from the previous quarter.
• Research and development expenses increased to $34.8 million, primarily due to $6.3 million in increased manufacturing costs related to the discontinued lirentelimab program.
• General and administrative expenses decreased to $10.9 million, reflecting a reduction in compensation and other costs.
• A non-cash impairment charge of $27.3 million was recognized due to a decline in market capitalization and the halting of the lirentelimab program.
• The company completed dosing in Phase 1 trials for both intravenous and subcutaneous AK006 in healthy volunteers.
• A Phase 1 trial of intravenous AK006 in patients with chronic spontaneous urticaria has been initiated.
• Allakos expects to report safety, pharmacokinetics, and pharmacodynamic results from the Phase 1 trials of AK006 in Q2 and Q3 2024.
• Topline data from the Phase 1 trial of intravenous AK006 in patients with chronic spontaneous urticaria is expected by year-end 2024.
• The company's restructuring activities are expected to extend the cash runway into mid-2026, with an estimated $81 to $86 million in cash, cash equivalents, and investments at the end of 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive clinical trial progress but significant financial losses and a large impairment charge. The increased net loss and cash burn are concerning, leading to a lower sentiment score.

Positives

• Allakos completed dosing in the Phase 1 trials for both intravenous and subcutaneous AK006 in healthy volunteers.
• The company initiated a Phase 1 trial of intravenous AK006 in patients with chronic spontaneous urticaria.
• Preclinical research on AK006's mechanism of action was published in Allergy.
• Restructuring activities are expected to extend the cash runway into mid-2026.
• The company expects to end 2024 with $81 to $86 million in cash, cash equivalents and investments.

Negatives

• Allakos experienced a significant increase in net loss, from $42.4 million in Q1 2023 to $71.1 million in Q1 2024.
• The company's cash position decreased by $31.5 million in the first quarter of 2024.
• Research and development expenses increased due to manufacturing costs related to the discontinued lirentelimab program.
• A $27.3 million non-cash impairment charge was recorded due to a decline in market capitalization and the halting of the lirentelimab program.

Risks

• The company's ability to successfully complete clinical trials for AK006 is subject to risks and uncertainties.
• There are risks associated with obtaining regulatory approvals for its clinical trials and product candidates.
• The company's ability to obtain additional capital to finance its operations is uncertain.
• Market acceptance of Allakos' product candidates is not guaranteed.
• The company's restructuring may not achieve the contemplated benefits.
• The company's ability to accurately forecast financial results is subject to risks.

Future Outlook

Allakos expects to report key data from its AK006 trials in the coming quarters and anticipates its restructuring will extend its cash runway into mid-2026. The company expects to end 2024 with $81 to $86 million in cash, cash equivalents and investments.

Management Comments

• The company reiterates that the restructuring activities will extend the cash runway into mid-2026.
• The company continues to expect to end 2024 with total cash, cash equivalents and investments in the range of $81 to $86 million.

Industry Context

Allakos is operating in the competitive biotechnology sector, focusing on developing treatments for allergic, inflammatory, and proliferative diseases. The company's focus on mast cell inhibition through Siglec-6 targeting is a novel approach, but it faces competition from other companies developing therapies for similar conditions.

Comparison to Industry Standards

• The increase in Allakos' net loss from $42.4 million to $71.1 million year-over-year is significant and may be viewed negatively compared to other biotech companies in the clinical stage.
• The company's cash burn of $31.5 million in Q1 2024 is substantial and needs to be monitored closely, especially in comparison to peers with similar pipelines.
• The $27.3 million non-cash impairment charge is a notable event and may indicate challenges in the company's asset valuation.
• The company's focus on AK006 and its novel mechanism of action is a potential differentiator, but its success will depend on clinical trial outcomes.
• Companies like Xencor and Regeneron are also developing treatments for inflammatory diseases, and their progress will be a key benchmark for Allakos.

Stakeholder Impact

• Shareholders will be concerned about the increased net loss and the decrease in cash position.
• Employees may be affected by the restructuring activities and potential future changes.
• Customers and partners will be interested in the progress of the AK006 clinical trials.
• Creditors will be monitoring the company's financial health and cash runway.

Next Steps

• Allakos will report safety, pharmacokinetics, and pharmacodynamic results from the Phase 1 trial of IV AK006 in healthy volunteers in Q2 2024.
• Allakos will report safety, pharmacokinetics, and pharmacodynamic results from the Phase 1 trial of SC AK006 in healthy volunteers in Q3 2024.
• Allakos will report topline data from the Phase 1 trial of IV AK006 in patients with CSU at year end 2024.

Key Dates

Keywords

Allakos, AK006, Clinical Trials, Biotechnology, Immunomodulatory Receptors, Mast Cells, Financial Results, Cash Runway, Restructuring, Siglec-6, Chronic Spontaneous Urticaria